EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants
Cardoso MJ (1), Wyld L (2), Rubio IT (3), Leidenius M (4), Curigliano G (5), Cutuli B (6), Marotti L (7), Biganzoli L (8).
(1) Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Nova Medical School, Lisbon, Portugal.
(2) Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
(3) Breast Surgical Oncology, Clínica Universidad de Navarra, Madrid, Universidad de Navarra, Spain.
(4 Breast Surgery Unit, Comprehensive Cancer Center Helsinki University Hospital, Madrid, Finland.
(5) Innovative Therapies Division and New Drug Development Program, Istituto Europeo di Oncologia, Milan, Medical Oncology, University of Milan, Milan, Italy.
(6) Institut du Cancer Courlancy, Reims, France.
(7) EUSOMA, Florence, Italy.
(8) Breast Unit, Nuovo Ospedale di Prato, Prato, Italy.
During the last two decades the number of breast implants used in aesthetic, oncologic and risk reducing surgery has increased substantially mainly due to the improvement and confirmed safety of these devices.
Since identification of the first case of anaplastic large cell lymphoma associated with a breast implant (BIA-ALCL) 20 years ago, there has been an increase in the number of reports of this very rare disease, demonstrating a clear association with breast implants. Whilst the majority of cases are localised and cured by implant removal and full capsulectomy, a small percentage require chemotherapy and the mortality rate is very low.
The evidence linking BIA-ALCL to implant surface texturing, as the majority of cases were diagnosed in patients with textured implants, has raised concerns about the long term safety of these devices resulting in patient and regulatory authority concerns globally.
We hereby present the current published knowledge about the link between BIA-ALCL and implant surface texture and a review of current regulatory and professional body advice across Europe, which may enable a better understanding of this rare disease, how to manage and ultimately prevent it.
We conclude by giving EUSOMA recommendation, towards the unnecessary change in attitudes towards implant based surgery, according to the most recent available published evidence as long as patients are properly informed about the risk of BIA-ALCL.
CITA DEL ARTÍCULO Breast. 2019 Jan 26;44:90-93. doi: 10.1016/j.breast.2019.01.011